Vanda turns up the heat on FDA in bid to renew Appointments Clause challenge
By Melissa Ritti ( April 8, 2025, 18:16 GMT | Insight) -- A lawsuit over the generic drug approval process in place at the US Food and Drug Administration should move forward, Vanda Pharmaceuticals said today. In seeking to nudge a DC federal judge to lift his unofficial stay, the brand drugmaker said the agency lulled the court into inaction when promising a response to its long-pending citizen petition this spring. Now, Vanda said, that response is expected in “late June.”Vanda Pharmaceuticals wants to see some progress in its Appointments Clause challenge to the approval process at the US Food and Drug Administration....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.